dimethyl (dimethoxyphosphinyl)cyclohexylmethylphosphate | 89187-49-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: dimethyl (dimethoxyphosphinyl)cyclohexylmethylphosphate
• 英文别名: Dimethyl {cyclohexyl[(dimethoxyphosphoryl)oxy]methyl}phosphonate；[cyclohexyl(dimethoxyphosphoryl)methyl] dimethyl phosphate
• CAS: 89187-49-5
• 化学式: C₁₁H₂₄O₇P₂
• 分子量: 330.255
• InChiKey: JIQGFQOTCOGWOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  Cyclohexanecarbonyl-phosphonic acid dimethyl ester 、 亚磷酸二甲酯 以58%的产率得到dimethyl (dimethoxyphosphinyl)cyclohexylmethylphosphate
  参考文献：
  名称：

  gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

  摘要：

  New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of numerous compounds has permitted the determination of the structural variations leading to optimal plasma lipid altering activity, indicating antiatherosclerotic potential. Among the compounds observed to be the most active, dimethyl alpha-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (20, SR-202, mifobate) was selected for further pharmacological and subsequent clinical development.

  DOI：

  10.1021/jm00391a027

文献信息

• NGUYEN, LAN M.;NIESOR, ERIC;BENTZEN, CRAIG L., J. MED. CHEM., 30,(1987) N 8, 1426-1433
  作者：NGUYEN, LAN M.、NIESOR, ERIC、BENTZEN, CRAIG L.

  DOI：——

  日期：——
• gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity
  作者：Nguyen Lan Mong、Eric Niesor、Craig L. Bentzen

  DOI：10.1021/jm00391a027

  日期：1987.8

  New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of numerous compounds has permitted the determination of the structural variations leading to optimal plasma lipid altering activity, indicating antiatherosclerotic potential. Among the compounds observed to be the most active, dimethyl alpha-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (20, SR-202, mifobate) was selected for further pharmacological and subsequent clinical development.